← All trials
NCT05854511
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 5, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Apr 13, 2024
- First posted
- May 11, 2023
- Last posted
- May 11, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityReponsible party - principal investigator
- Cairo UniversityCollaborator
- Ain Shams UniversitySponsor investigator
- Ain Shams UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.